Although the inhibitor declined during treatment, an anamnestic response was recorded on two occasions. A continuous high dose F VIII regimen of 2oo units per kg per day resulted in reduction of the inhibitor concentration to less than 1 unit per ml. No anamnestic response was seen after a ...
www.nature.com/scientificreports OPEN Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular received: 04 October 2016 accepted: 20 February 2017 Published: 22 March 2017 trafficking defects in coagulation factor VIII Wei Wei1,2, Chunlei Zheng1, Min...
High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood. 2005;106(10):3415-3422... C Hausl - 《Blood》 被引量: 123发表: 2005年 Single Cell Analysis of Factor VIII-specific T Cells in Hemophilic Mice after Treatment with Human...
A HIGH-YIELD FACTOR VIII CONCENTRATE SUITABLE FOR ADVANCED HEAT TREATMENT The heat treatment of Factor VIII concentrates in the freeze-dried state has been widely adopted to inactivate Human Immunodeficiency Virus (HIV) which may be present. However, the degree of heating that can be applied has ...
not affect secretion, although the specific activity of factor VIII was slightly increased[45], Thus, the presence of complex oligosaccharide was not required for secretion or functional activity of factor VIII.A23187treatment inhibited addition of serine/threonine (O)-linked glycans to factor VIII....
Factor VIII used for infusion is a highly purified concentrate of factor VIII: C, the coagulant portion of the factor VIII complex. Factor VIII: C acts as a cofactor to factor IX and the two together activate factor X and the cascade of the coagulation process for the formation of ablood...
of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment. ...
Von Willebrand factor (vWF) concentrates (I) containing Factor VIII:C (FVIII:C) are obtained by fractional precipitation from a liquid containing FVIII:C and vWF; and have an elevated content of high molecular multimers of vWF and a ratio of vWF:RCoF (ristocetin cofactor) activity to vWF:Ag...
Lusher, J. M. 1996. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 26:124–130. PubMedCASGoogle Scholar Lusher, J. M. 2000. Acute hemarthroses: the benefits of early versus late treatment with recombinant...
The infusion of high purity Factor VIII and Factor IX concentrates represent one of the best alternatives in the treatment of haemophilia A and haemophilia... E Ronzi,A Capolongo,G Rovero,... - 《Chemical Engineering & Processing Process Intensification》 被引量: 5发表: 2003年 ...